# Structural modeling and functional characterization of a novel gain-of-function TLR8 variant causing severe inflammatory syndrome

**Authors:** Nikolaos T. Skenteris, Elisa Luttermann, Sanjana Nair, Ioannis Evangelakos, Maria Pujantell, Marie Eggers, Fabian Hausmann, Marleen Bérouti, Benedetta Padoan, Felix J. Flomm, Janna M. Claussen, Benjamin Grünhagel, Anika Salfelder, Brigitte Beifuss, Saskia Biskup, Patrick Blümke, Katrin Rading, Heike Hildebrandt, Urte Matschl, Silke Giesemann-Jansen, Jana Hennesen, Viacheslav O. Nikolaev, Michael Kutsche, Christian Kubisch, Friedrich Koch-Nolte, Nicola M. Tomas, Eva Tolosa, Marc Lütgehetmann, Felix R. Stahl, Veit Hornung, Madeleine J. Bunders, Christian Schlein, Maya Topf, Ina Kötter, Marcus Altfeld

PMC · DOI: 10.1172/jci.insight.187422 · JCI Insight · 2026-02-23

## TL;DR

A new TLR8 gene mutation leads to immune overactivation and inflammation in two siblings, showing how genetic changes can cause immune system dysfunction.

## Contribution

Identifies a novel TLR8 gain-of-function mutation causing severe immunopathology through integrated structural and functional analysis.

## Key findings

- The TLR8 A518T variant increases NF-κB activation and proinflammatory cytokine secretion.
- The mutation causes faster TLR8 protein degradation and increased proteasomal turnover.
- Structural modeling shows enhanced stabilization of the TLR8 homodimer interface due to the mutation.

## Abstract

With the increasing use of genetic sequencing to investigate inborn errors of immunity, rare variants are frequently identified, yet their clinical relevance often remains uncertain. Establishing pathogenicity requires a multidisciplinary approach that integrates genetic, structural, functional, and clinical data. Here, we used such a strategy to investigate a previously unreported hemizygous missense variant — alanine (A) to threonine (T) at residue 518 — in Toll-like receptor 8 (TLR8), identified in 2 male siblings with recurrent infections and systemic inflammation, characterized by a proinflammatory immune signature and B cell dysregulation. Functional studies showed that the TLR8 A518T variant enhanced NF-κB activation and increased secretion of proinflammatory cytokines compared with WT TLR8 upon stimulation, consistent with a gain-of-function effect. Protein degradation and turnover assays revealed reduced abundance of the mutant TLR8 protein due to faster turnover and increased proteasomal degradation. Computational modeling predicted enhanced structural stabilization of the active TLR8 homodimer interface via additional water-mediated hydrogen bonds introduced by the A518T substitution. Together, these findings integrating structural modeling with functional assays identify a novel TLR8 ligand-specific gain-of-function mutation resulting in complex immunopathology in 2 siblings.

A newly discovered TLR8 gene mutation causes immune overactivation and inflammation in two siblings, linking genetic change to immune system dysfunction and disease.

## Linked entities

- **Genes:** TLR8 (toll like receptor 8) [NCBI Gene 51311]
- **Proteins:** TLR8 (toll like receptor 8), NFKB1 (nuclear factor kappa B subunit 1)

## Full-text entities

- **Genes:** DNAJC21 (DnaJ heat shock protein family (Hsp40) member C21) [NCBI Gene 134218] {aka BMFS3, DNAJA5, GS3, JJJ1}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, IFIT3 (interferon induced protein with tetratricopeptide repeats 3) [NCBI Gene 3437] {aka CIG-49, GARG-49, IFI60, IFIT4, IRG2, ISG60}, HSPA6 (heat shock protein family A (Hsp70) member 6) [NCBI Gene 3310] {aka HSP70B'}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, MX1 (MX dynamin like GTPase 1) [NCBI Gene 4599] {aka IFI-78K, IFI78, MX, MxA, lncMX1-215}, CD27 (CD27 molecule) [NCBI Gene 939] {aka S152, S152. LPFS2, T14, TNFRSF7, Tp55}, CD80 (CD80 molecule) [NCBI Gene 941] {aka B7, B7-1, B7.1, BB1, CD28LG, CD28LG1}, CR2 (complement C3d receptor 2) [NCBI Gene 1380] {aka C3DR, CD21, CR, CVID7, SLEB9}, CCL20 (C-C motif chemokine ligand 20) [NCBI Gene 6364] {aka CKb4, Exodus, LARC, MIP-3-alpha, MIP-3a, MIP3A}, HSPA1B (heat shock protein family A (Hsp70) member 1B) [NCBI Gene 3304] {aka HSP70-1, HSP70-1B, HSP70-2, HSP70.1, HSP70.2, HSP72}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, IL3RA (interleukin 3 receptor subunit alpha) [NCBI Gene 3563] {aka CD123, IL-3R-alpha, IL3R, IL3RAY, IL3RX, IL3RY}, IFNB1 (interferon beta 1) [NCBI Gene 3456] {aka IFB, IFF, IFN-beta, IFNB}, CCL4 (C-C motif chemokine ligand 4) [NCBI Gene 6351] {aka ACT2, AT744.1, G-26, HC21, LAG-1, LAG1}, CD40LG (CD40 ligand) [NCBI Gene 397231] {aka CD40L, TNFSF5}, DNAJB1P1 (DNAJB1 pseudogene 1) [NCBI Gene 171221] {aka DNAJB1P, HSP40, psiHSP40}, CD4 (CD4 molecule) [NCBI Gene 404704], IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, TLR7 (toll like receptor 7) [NCBI Gene 51284] {aka IMD74, SLEB17, TLR7-like}, IFIT2 (interferon induced protein with tetratricopeptide repeats 2) [NCBI Gene 3433] {aka G10P2, GARG-39, IFI-54, IFI-54K, IFI54, IFIT-2}, CCL19 (C-C motif chemokine ligand 19) [NCBI Gene 6363] {aka CKb11, ELC, MIP-3b, MIP3B, SCYA19}, FOS (Fos proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 2353] {aka AP-1, C-FOS, p55}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}, IL3 (interleukin 3) [NCBI Gene 3562] {aka IL-3, MCGF, MULTI-CSF}, OAS2 (2'-5'-oligoadenylate synthetase 2) [NCBI Gene 4939] {aka AIAISD2}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, HERC5 (HECT and RLD domain containing E3 ubiquitin protein ligase 5) [NCBI Gene 51191] {aka CEB1, CEBP1}, THBD (thrombomodulin) [NCBI Gene 7056] {aka AHUS6, BDCA-3, BDCA3, CD141, THPH12, THRM}, RP2 (RP2 activator of ARL3 GTPase) [NCBI Gene 6102] {aka DELXp11.3, NM23-H10, NME10, TBCCD2, XRP2}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, TBL1XR1 (TBL1X/Y related 1) [NCBI Gene 79718] {aka C21, DC42, IRA1, MRD41, TBLR1}, OAS1 (2'-5'-oligoadenylate synthetase 1) [NCBI Gene 4938] {aka E18/E16, IFI-4, IMD100, OIAS, OIASI}, HERC6 (HECT and RLD domain containing E3 ubiquitin protein ligase family member 6) [NCBI Gene 55008], TLR8 (toll like receptor 8) [NCBI Gene 51311] {aka CD288, IMD98, TLR-8, hTLR8}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CD28 [NCBI Gene 100738615], CD38 (CD38 molecule) [NCBI Gene 952] {aka ADPRC 1, ADPRC1, cADPR1}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, ICOS (inducible T cell costimulator) [NCBI Gene 733597], EGR1 (early growth response 1) [NCBI Gene 1958] {aka AT225, G0S30, KROX-24, NGFI-A, TIS8, ZIF-268}, KLF4 (KLF transcription factor 4) [NCBI Gene 9314] {aka EZF, GKLF}, CD3E (CD3 epsilon subunit of T-cell receptor complex) [NCBI Gene 397455] {aka CD3}, CD14 (CD14 molecule) [NCBI Gene 929], AR (androgen receptor) [NCBI Gene 367] {aka AIS, AR8, DHTR, HPCX3, HUMARA, HYSP1}, IRF7 (interferon regulatory factor 7) [NCBI Gene 3665] {aka IMD39, IRF-7, IRF-7H, IRF7A, IRF7B, IRF7C}, IFI44L (interferon induced protein 44 like) [NCBI Gene 10964] {aka C1orf29, GS3686, TLDC5B}, CD79A (CD79a molecule) [NCBI Gene 973] {aka IGA, IGAlpha, MB-1, MB1}, FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}, IFIT1 (interferon induced protein with tetratricopeptide repeats 1) [NCBI Gene 3434] {aka C56, G10P1, IFI-56, IFI-56K, IFI56, IFIT-1}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, CXCR5 (C-X-C motif chemokine receptor 5) [NCBI Gene 100515679] {aka CD185}, RNF144B (ring finger protein 144B) [NCBI Gene 255488] {aka IBRDC2, PIR2, bA528A10.3, p53RFP}, CSF1 (colony stimulating factor 1) [NCBI Gene 1435] {aka CSF-1, MCSF, PG-M-CSF}
- **Diseases:** impaired erythropoiesis (MESH:C563479), lymphadenopathy (MESH:D008206), leukopenia (MESH:D007970), autoimmune (MESH:D001327), splenomegaly (MESH:D013163), allergic reaction (MESH:D004342), Schwachman-Diamond syndrome (MESH:C535645), autoinflammatory diseases (MESH:D056660), immune cell dysregulation (OMIM:614878), HIV disease (MESH:D015658), DNAJC21-related diseases (MESH:D000077733), genetic diseases (MESH:D030342), B cell abnormalities (MESH:D015448), fever (MESH:D005334), bone marrow failure (MESH:D000080983), chronic (MESH:D002908), polyarteritis nodosa (MESH:D010488), respiratory infections (MESH:D012141), anemia (MESH:D000740), autoimmune vasculitis (MESH:D014657), chronic inflammatory syndrome (MESH:D020277), Inflammatory (MESH:D007249), inherited bone marrow failure syndrome (MESH:D000080984), rheumatoid arthritis (MESH:D001172), cerebral vasculitis (MESH:D020293), intellectual disability (MESH:D008607), IgG (MESH:D017099), leukemia (MESH:D007938), infection (MESH:D007239), inflammatory syndrome (MESH:D018746), thrombocytopenia (MESH:D013921), cerebral ischemia (MESH:D002545), IEI (MESH:D007154), cerebral infarctions (MESH:D002544), antiphospholipid syndrome (MESH:D016736), spastic hemiparesis (MESH:D010291), toxicity (MESH:D064420), Immunoglobulin deficiencies (MESH:D004406), impaired humoral immunity (MESH:C562390)
- **Chemicals:** CS (MESH:D002586), water (MESH:D014867), l-glutamine (MESH:D005973), adalimumab (MESH:D000068879), MG132 (MESH:C072553), CHX (MESH:D003513), hydrogen (MESH:D006859), glucose (MESH:D005947), infliximab (MESH:D000069285), cyclophosphamide (MESH:D003520), mycophenolic acid (MESH:D009173), CRC1648 (-), doxycycline hyclate (MESH:D004318), penicillin (MESH:D010406), uridine (MESH:D014529), oxygen (MESH:D010100), beta-estradiol (MESH:D004958), nitrogen (MESH:D009584), TL8-506 (MESH:C000723777), azathioprine (MESH:D001379), streptomycin (MESH:D013307)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Mutations:** rs1266840568, c.1552G>A, alanine (A) with threonine (T), A518T, p.F492V, D543A, F494L, c.-171del, rs2147259148,  alanine (A) to threonine (T) at residue 518,  alanine (A) to threonine (T) at residue 518, G572V
- **Cell lines:** HEK BN1 — Homo sapiens (Human), Transformed cell line (CVCL_A7YP), CF — Homo sapiens (Human), Cystic fibrosis, Embryonic stem cell (CVCL_A239), BLaER1 — Homo sapiens (Human), Childhood B acute lymphoblastic leukemia, Cancer cell line (CVCL_VQ57), HEK293T — Homo sapiens (Human), Transformed cell line (CVCL_0063)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12956005/full.md

## Figures

13 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12956005/full.md

## References

51 references — full list in the complete paper: https://tomesphere.com/paper/PMC12956005/full.md

---
Source: https://tomesphere.com/paper/PMC12956005